José Jiménez
About
José Jiménez is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, José Jiménez has authored 39 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 17 papers in Cancer Research and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in José Jiménez's work include HER2/EGFR in Cancer Research (13 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Cancer Genomics and Diagnostics (9 papers). José Jiménez is often cited by papers focused on HER2/EGFR in Cancer Research (13 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Cancer Genomics and Diagnostics (9 papers). José Jiménez collaborates with scholars based in Spain, United States and Palestinian Territory. José Jiménez's co-authors include José Baselga, Marta Guzmán, Maurizio Scaltriti, Santiago Ramón y Cajal, Claudia Aura, Joaquı́n Arribas, Stefania Landolfi, Aleix Prat, Magüi Gili and Pieter J.A. Eichhorn and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.
In The Last Decade
José Jiménez
37 papers receiving 1.6k citations
Peers
José Jiménez
Thomas Holbro Switzerland
Iwan Beuvink Switzerland
Joan T. Garrett United States
Samuel W. Brady United States
Thinh Q. Pham United States
Xuewu Zhang China
Xenia Jimenez United States
Keng‐Hsueh Lan Taiwan
María G. Kuba United States
Mythili Shastry United States
Citations per year, relative to José Jiménez José Jiménez (= 1×)
peers
Thomas Holbro
Countries citing papers authored by José Jiménez
Since
Specialization
Citations
This map shows the geographic impact of José Jiménez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José Jiménez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José Jiménez more than expected).
Fields of papers citing papers by José Jiménez
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by José Jiménez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José Jiménez. The network helps show where José Jiménez may publish in the future.
Co-authorship network of co-authors of José Jiménez
This figure shows the co-authorship network connecting the top 25 collaborators of José Jiménez. A scholar is included among the top collaborators of José Jiménez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José Jiménez. José Jiménez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Toledo, Rodrigo A., Oriol Mirallas, Ana Carolina Ramos Moreno, et al.. (2024). Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.. Journal of Clinical Oncology. 42(16_suppl). 2510–2510.
2.
Zamora, Esther, Santiago Escrivá-de-Romaní, José Jiménez, et al.. (2022). Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response. Therapeutic Advances in Medical Oncology. 14. 4287551633–4287551633.
3.
Frigola, Joan, Caterina Carbonell, Patricia Iranzo, et al.. (2022). High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC. Journal for ImmunoTherapy of Cancer. 10(4). e004197–e004197.
4.
Eshwaraiah, Mallikarjuna Siraganahalli, Cristina Saura, Patricia Gómez, et al.. (2022). A retrospective validation of CanAssist Breast in European early-stage breast cancer patient cohort. The Breast. 63. 1–8.
5.
Serna, Garazi, S. Simonetti, Roberta Fasani, et al.. (2020). Sequential immunohistochemistry and virtual image reconstruction using a single slide for quantitative KI67 measurement in breast cancer. The Breast. 53. 102–110.
6.
Serna, Garazi, Jorge Hernando, Roberta Fasani, et al.. (2020). Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Annals of Oncology. 31(10). 1366–1375.
7.
Iranzo, Patricia, Ana Callejo, Alejandro Navarro, et al.. (2020). Immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients with WNT pathway mutations (APC/CTNNB1).. Journal of Clinical Oncology. 38(15_suppl). e15137–e15137.
8.
Serna, Garazi, Franco Cecchi, Roberta Fasani, et al.. (2019). Targeted multiplex proteomics for molecular prescreening and biomarker discovery in metastatic colorectal cancer. Scientific Reports. 9(1). 13568–13568.
9.
Nucíforo, Paolo, Claudia Aura, Eileen Holmes, et al.. (2015). Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Annals of Oncology. 26(7). 1494–1500.
10.
Nucíforo, Paolo, Sheeno Thyparambil, Claudia Aura, et al.. (2015). High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti‐HER2 therapy. Molecular Oncology. 10(1). 138–147.
11.
Nucíforo, Paolo, Sheeno Thyparambil, Claudia Aura, et al.. (2015). Abstract P4-11-29: Quantitative measurement of HER2 levels by multiplexed mass spectrometry from FFPE tissue predicts survival in patients treated with anti-HER2 based therapy. Cancer Research. 75(9_Supplement). P4–11.
12.
Capdevila, Jaume, Ana Vivancos, Xavier Matías‐Guiu, et al.. (2015). Genomic landscape of anaplastic thyroid cancer.. Journal of Clinical Oncology. 33(15_suppl). 6033–6033.
13.
Nucíforo, Paolo, Sheeno Thyparambil, Ana C. Garrido-Castro, et al.. (2014). Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.. Journal of Clinical Oncology. 32(15_suppl). 649–649.
14.
Eichhorn, Pieter J.A., Laura Rodón, Alba Gonzàlez-Juncà, et al.. (2012). USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nature Medicine. 18(3). 429–435.
15.
Scaltriti, Maurizio, Pieter J.A. Eichhorn, Javier Cortés, et al.. (2011). Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients. Proceedings of the National Academy of Sciences. 108(9). 3761–3766.
16.
Scaltriti, Maurizio, Violeta Serra, Emmanuel Normant, et al.. (2011). Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Molecular Cancer Therapeutics. 10(5). 817–824.
17.
Scaltriti, Maurizio, Sarat Chandarlapaty, Ludmila Prudkin, et al.. (2010). Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research. 16(9). 2688–2695.
18.
Scaltriti, Maurizio, Chandra Verma, Marta Guzmán, et al.. (2008). Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene. 28(6). 803–814.
19.
Cosimo, Serena Di, Maurizio Scaltriti, Federico Rojo, et al.. (2007). The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. Journal of Clinical Oncology. 25(18_suppl). 3511–3511.
20.
Cosimo, Serena Di, Joan Seoane, Marta Guzmán, et al.. (2005). Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy. Journal of Clinical Oncology. 23(16_suppl). 3112–3112.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Thomas Holbro Breakdown of academic impact, for papers by Iwan Beuvink Breakdown of academic impact, for papers by Joan T. Garrett Breakdown of academic impact, for papers by Samuel W. Brady Breakdown of academic impact, for papers by Thinh Q. Pham Breakdown of academic impact, for papers by Xuewu Zhang Breakdown of academic impact, for papers by Xenia Jimenez Breakdown of academic impact, for papers by Keng‐Hsueh Lan Breakdown of academic impact, for papers by María G. Kuba Breakdown of academic impact, for papers by Mythili Shastry